David Liew drdavidliew
6 years 4 months ago
Does TCZ actually fix GCA?
@nihrheumatology cohort w serial PET/CT q6m:
FDG uptake (PETVAS) reduces longitudinally over 2y but does not normalise, w rebound on TCZ cessation
Ongoing reductions in year 2? GCA doesn't sleep.
@KQuinnRheum @petercgrayson OP0144 #EULAR2020 @RheumNow https://t.co/aczQbONcNc
Janet Pope Janetbirdope
6 years 4 months ago
Our study shows that HCQ retinopathy virtually never occurs in first 5 yrs, SLE has more risk than other diseases such as RA and chloroquine has a far higher risk of retinal toxicity OP0333 #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/ZzRy3po4yw
David Liew drdavidliew
6 years 4 months ago
Serum calprotectin as a biomarker in ANCA-associated vasculitis is enticing, and not just during induction:
during maintenance following remission, it might predict relapse and renal decline independently of disease characteristics
MAINRITSAN data OP0031 #EULAR2020 @RheumNow https://t.co/ItI0BPGrUX
k dao KDAO2011
6 years 4 months ago
#EULAR2020 OP0167 Results are finally in!!
MMF can be safely w/drawn in quiescent SLE: prospect RCT (nonblinded) 102 pts. MMF tapered over 12 weeks, f/u 60 weeks; no sig diff for flares in pts who stopped MMF vs. maintained; pts who cont MMF had ⬆️ minor infections. @rheumnow https://t.co/bOnuEBLis9
David Liew drdavidliew
6 years 4 months ago
So #EULAR2020 was meant to be in Germany, and I was meant to go. I am currently not in Germany.
Germany can come to me!
Just getting into the #EULAR2020goesvirtual spirit @RheumNow https://t.co/RxeTwunR0K
Dr. John Cush RheumNow
6 years 4 months ago
When starting IV Pegloticase in #Gout, Do you start a DMARD too? #EULAR2020
Dr. John Cush RheumNow
6 years 4 months ago
RheumNow Podcast is up! The Future of JAKs. Watch it here>> https://t.co/Ot483P99RB or listen to the Podcast on iTunes>>https://t.co/FHJv01AAbC or on SoundCloud>>https://t.co/1ImZzhb0mS
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
In difficult times, it's reassuring to reflect on the similarities that bring us together. In the case of the EULAR and ACR COVID19 guidelines as discussed at #EULAR2020 by Drs. Mikuls and Landewe, the recommendations from both panels proved to be reassuring with a hint of "we are flying blindly into the unknown."
Dr. John Cush RheumNow
6 years 4 months ago
Tofacitinib shown to be effective (vs Placebo) in 225 Polyarticular JIA (included some ERA & PsA). with less flares (29 vs 53%) and higher JCR30 responses (71 vs 47%) @6mos #EULAR2020 #OP0281 https://t.co/3BnZeB4ROr https://t.co/4pTLbTtBdN
Dr. John Cush RheumNow
6 years 4 months ago
CDC guidelines for Rx of Latent Tuberculosis; Preferred: A) 3 months of once-weekly INH plus rifapentine (3HP); B) 4 months of daily rifampin (4R); C) 3 months of daily INH plus rifampin (3HR) - Shorter, safer, effective with higher completion rates. https://t.co/a2iZczFTP2
Dr. John Cush RheumNow
6 years 4 months ago
Lancet has issued an almost retraction - an "Expression of Concern" alerting readers that many have voiced scientific concerns about the Lancet HCQ/CQ paper w/ more deaths. MORE DEATHS COULD HAVE BEEN FROM THE DRUGS OR THE DRUGS BEING USED IN SICKER PTS https://t.co/saoE32qpuF
A Lancet systematic review and meta-analysis provides the basis for physical distancing and the value of making as measures to prevent infection with coronavirus 2 (SARS-CoV-2) or COVID-19.
The analysis included 172 observational studies, no randomised controlled trials and 44 relevant comparative studies involving 25 697 patients.
NEJM has reported that the use of hydroxychloroquine did not prevent symptomatic COVID-19 infection when used within 4 days after SARS-CoV-2 exposure.
Currently for persons who are COVID exposed, the standard of care is quarantine and there is no known preventative therapy.
